Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978289316> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W1978289316 endingPage "225" @default.
- W1978289316 startingPage "224" @default.
- W1978289316 abstract "The legal question whether RU-486 can meet the standards for US Food and Drug Administration (FDA) approval for a drug indicated for abortion can be answered in the affirmative. Under the Food, Drug, and Cosmetic Act, efficacy must be demonstrated by evidence consisting of adequate and well-controlled investigations to show that a drug is safe and effective for its intended use. The FDA will approve it if on the basis of the clinical trials it could be concluded that the drug will have the effect it purports as prescribed in the labeling, and if the drug is safe. In congressional hearings and in the newspapers the so-called import alert issued by the FDA to prevent the importing of RU-486 under certain circumstances has been publicized. The import alert is no bar to conducting clinical studies in the US under an investigational new drug application (IND) nor is the import alert a bar to the filing and the pursuit of a new drug application (NDA) to allow marketing in the US. The import alert is no bar to anything except importation without an IND or NDA. The real problem is that there is no seller of RU-486 in the US and no sponsor of an NDA offering clinical evidence of safety and efficacy as well as the ability to manufacture the drug and the necessary prostaglandins properly. In additions to abortion, other uses of RU-486 include contraception, breast cancer, and Cushing syndrome. Some limited research could be done under INDs with small supplies of the drug obtained elsewhere on the world market. There are only 2 solutions to this problem. One is that Roussel must change its mind or have its mind changed as the example of the AIDS community showed, which has managed to induce the development of drugs that were impossible 8 or 10 years ago. The other solution is to found a pharmaceutical company that could induce competition for manufacturing RU-486." @default.
- W1978289316 created "2016-06-24" @default.
- W1978289316 creator A5024132518 @default.
- W1978289316 date "1992-01-01" @default.
- W1978289316 modified "2023-10-14" @default.
- W1978289316 title "RU 486, the FDA and Free Enterprise" @default.
- W1978289316 cites W2339185636 @default.
- W1978289316 doi "https://doi.org/10.1111/j.1748-720x.1992.tb01193.x" @default.
- W1978289316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1434765" @default.
- W1978289316 hasPublicationYear "1992" @default.
- W1978289316 type Work @default.
- W1978289316 sameAs 1978289316 @default.
- W1978289316 citedByCount "0" @default.
- W1978289316 crossrefType "journal-article" @default.
- W1978289316 hasAuthorship W1978289316A5024132518 @default.
- W1978289316 hasConcept C104863432 @default.
- W1978289316 hasConcept C108827166 @default.
- W1978289316 hasConcept C112698675 @default.
- W1978289316 hasConcept C126322002 @default.
- W1978289316 hasConcept C144133560 @default.
- W1978289316 hasConcept C201280247 @default.
- W1978289316 hasConcept C2778642596 @default.
- W1978289316 hasConcept C2779234561 @default.
- W1978289316 hasConcept C2780035454 @default.
- W1978289316 hasConcept C3018890749 @default.
- W1978289316 hasConcept C41008148 @default.
- W1978289316 hasConcept C4892016 @default.
- W1978289316 hasConcept C502991105 @default.
- W1978289316 hasConcept C512399662 @default.
- W1978289316 hasConcept C535046627 @default.
- W1978289316 hasConcept C54355233 @default.
- W1978289316 hasConcept C71924100 @default.
- W1978289316 hasConcept C86803240 @default.
- W1978289316 hasConcept C98274493 @default.
- W1978289316 hasConceptScore W1978289316C104863432 @default.
- W1978289316 hasConceptScore W1978289316C108827166 @default.
- W1978289316 hasConceptScore W1978289316C112698675 @default.
- W1978289316 hasConceptScore W1978289316C126322002 @default.
- W1978289316 hasConceptScore W1978289316C144133560 @default.
- W1978289316 hasConceptScore W1978289316C201280247 @default.
- W1978289316 hasConceptScore W1978289316C2778642596 @default.
- W1978289316 hasConceptScore W1978289316C2779234561 @default.
- W1978289316 hasConceptScore W1978289316C2780035454 @default.
- W1978289316 hasConceptScore W1978289316C3018890749 @default.
- W1978289316 hasConceptScore W1978289316C41008148 @default.
- W1978289316 hasConceptScore W1978289316C4892016 @default.
- W1978289316 hasConceptScore W1978289316C502991105 @default.
- W1978289316 hasConceptScore W1978289316C512399662 @default.
- W1978289316 hasConceptScore W1978289316C535046627 @default.
- W1978289316 hasConceptScore W1978289316C54355233 @default.
- W1978289316 hasConceptScore W1978289316C71924100 @default.
- W1978289316 hasConceptScore W1978289316C86803240 @default.
- W1978289316 hasConceptScore W1978289316C98274493 @default.
- W1978289316 hasIssue "3" @default.
- W1978289316 hasLocation W19782893161 @default.
- W1978289316 hasLocation W19782893162 @default.
- W1978289316 hasOpenAccess W1978289316 @default.
- W1978289316 hasPrimaryLocation W19782893161 @default.
- W1978289316 hasRelatedWork W2025539591 @default.
- W1978289316 hasRelatedWork W2086383155 @default.
- W1978289316 hasRelatedWork W2157531023 @default.
- W1978289316 hasRelatedWork W2171212942 @default.
- W1978289316 hasRelatedWork W2273158204 @default.
- W1978289316 hasRelatedWork W2324705480 @default.
- W1978289316 hasRelatedWork W2388075619 @default.
- W1978289316 hasRelatedWork W3122951664 @default.
- W1978289316 hasRelatedWork W3129888337 @default.
- W1978289316 hasRelatedWork W4301195367 @default.
- W1978289316 hasVolume "20" @default.
- W1978289316 isParatext "false" @default.
- W1978289316 isRetracted "false" @default.
- W1978289316 magId "1978289316" @default.
- W1978289316 workType "article" @default.